13C NMR (101 MHz, DMSO) δ 155.11, 142.83, 131.26, 130.94, 117.81, 114.17, 41.76, 33.47.
Synthesis of 1-(3,5-Bis(trifluoromethyl)phenyl)-3-(2-azidoethyl)urea (7)
1-(3,5-Bis(trifluoromethyl)phenyl)-3-(2-bromoethyl)urea (900 mg, 2.34 mmol) was dissolved
in DMF (40 mL) at rt and sodium azide (385 mg, 5.93 mmol), and a few mg of KI were
added. The resulting mixture was stirred for 24 h at 80°C. It was then poured into water (300
mL) and extracted with diethyl ether. The combined organic layers were then evaporated
under reduced pressure and purified on silica gel using a 30:70 mixture of ethyl
acetate:hexanes, affording 450 mg (1.3 mmol, 55%) of azide.
1H NMR (400 MHz, DMSO) δ 9.34 (s, 1H), 8.09 (s, 2H), 7.54 (s, 1H), 6.67 (t, J = 5.6 Hz,
1H), 3.42 (t, J = 5.8 Hz, 2H), 3.32 (q, J = 5.4 Hz, 2H).
13C NMR 13C NMR (101 MHz, DMSO) δ 154.79, 142.41, 130.75, 130.43, 117.34, 113.58,
50.38, 38.99.
Synthesis of receptors 8a-d
Mono-2-propargyl-β-CD 1 (1 g, 0.85 mmol) and the selected azide (1.1 equiv.) were
dissolved in a 4:1 mixture of DMSO and water (30 mL). Tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine (TBTA, ca. 20 mg) was added. The mixture was deaerated by passing argon
through the solution. CuSO4 (0.1 equiv., aqueous solution) and sodium ascorbate (0.2 equiv.,
aqueous solution) were added dropwise into the stirred reaction mixture, which was further
stirred for 24 h at 50°C. After the removal of the catalyst (via the addition of ammonia to the
reaction mixture and its passage through a thin pad of silica gel) the solvents were evaporated
under reduced pressure and the crude product was dissolved in water (5 mL) and precipitated
with acetone (500 mL). The precipitate was filtered and air dried.
(S)-2-O-((1-(2-(3-Phenylureido)-4-methylpentyl)-1H-1,2,3-triazol-4-yl)methyl)-β-CD (8a)
1H NMR (500 MHz, DMSO) δ 8.40 (s, 1H), 8.07 (s, 1H), 7.36 (d, J = 7.6 Hz, 2H), 7.25 – 7.15
(m, 2H), 6.89 (t, J = 7.3 Hz, 2H), 6.08 (s, 3H), 5.90 (d, J = 6.5 Hz, 3H), 5.80 – 5.59 (m, 7H),
4.94 – 4.74 (m, 7H), 4.66 – 4.54 (m, 2H), 4.53 – 4.36 (m, 7H), 4.09 (dd, J = 16.5, 4.2 Hz, 2H),
3.74 – 3.48 (m, 21H), 3.32 (s, 22H), 1.73 – 1.59 (m, 2H), 1.32 – 1.11 (m, 1H), 0.86 (dd, J =
16.2, 6.6 Hz, 6H).
13C NMR (126 MHz, DMSO) δ 128.64, 124.93, 121.14, 117.70, 101.93, 101.53, 100.27,
82.07, 81.59, 81.52, 81.21, 79.43, 73.25, 73.04, 72.95, 72.67, 72.48, 72.38, 72.22, 72.02,
71.75, 71.69, 64.42, 60.02, 59.91, 53.52, 47.41, 42.88, 36.67, 29.02, 28.70, 24.12, 23.18,
21.64.
HRMS ESI+ m/z: 1434.5519 (MH+, C58H91N5O36H+ requires 1434.5517); 1456.5321 (MNa+,
C58H91N5O36Na+ requires 1456.5336).
(S)-2-O-((1-(2-(3-(4-Nitrophenyl)-ureido)-4-methylpentyl)-1H-1,2,3-triazol-4-yl)methyl)-β-
CD (8b)
1H NMR (500 MHz, DMSO) δ 9.25 (s, 1H), 8.11 (t, J = 13.8 Hz, 3H), 7.53 (dd, J = 53.5, 7.4
Hz, 2H), 6.48 (s, 1H), 6.09 – 5.47 (m, 11H), 4.99 – 4.66 (m, 7H), 4.66 – 4.30 (m, 7H), 4.09
(d, J = 43.9 Hz, 1H), 3.81 (t, J = 9.3 Hz, 1H), 3.75 – 3.46 (m, 22H), 3.46 – 3.09 (m, 22H),
1.64 (s, 2H), 1.27 (dd, J = 53.3, 40.5 Hz, 3H), 0.87 (dd, J = 17.3, 5.6 Hz, 6H).
13C NMR (126 MHz, DMSO) δ 128.76, 127.76, 125.14, 124.97, 116.98, 101.96, 101.54,
100.32, 84.40, 82.12, 81.63, 81.57, 81.46, 81.17, 79.46, 73.30, 73.07, 72.97, 72.71, 72.52,
5